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Key messages: 
• B-cells from CdLS patients have altered IGH repertoires with a reduced 
diversity and skewed VH usage. 
• The frequency of somatic hypermutations is reduced in the IGHV regions in 
B-cells from NIPBL mutated CdLS patients. 
• Inefficient immunoglobulin gene recombination/diversification may underlie 
the susceptibility to infection in CdLS patients. 
 
Capsule summary: Altered IGH repertoires with reduced diversity, skewed VH gene 
usage and reduced frequency of somatic hypermutation were observed in CdLS 
patients. 
 
Key words: CdLS, cohesin, NIPBL, SMC1A, immunoglobulin, V(D)J 
recombination, somatic hypermutation, B-cells, human.  
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To the Editor, 
 
B-cells rely on a broad receptor repertoire to provide protection against a wide range 
of pathogens. This is in part achieved via V(D)J recombination which, by assembling 
various combinations of variable (V), diversity (D) and joining (J) genes, creates 
different immunoglobulin (Ig) V regions(1). The recombination processes is initiated 
by RAG1/RAG2 enzymes and requires a functional non-homologous end joining 
(NHEJ) machinery. B-cells can further diversify their Ig V regions through somatic 
hypermutation (SHM), to improve the affinity between the antibody and antigen, and 
switch the isotype of antibody produced by class switch recombination (CSR). Both 
processes are initiated by activation-induced cytidine deaminase (AID) and rely on 
transcription and a number of DNA repair mechanisms.  
 
Cornelia de Lange syndrome (CdLS) is a rare, multisystem developmental disorder 
characterized by typical facial features, intellectual disability and multiple congenital 
anomalies(2). Most CdLS patients have deleterious mutations in the gene encoding 
the cohesin loader NIPBL, but mutations in other cohesin related genes SMC1A, 
SMC3, PDS5B, RAD21 or HDAC8 have also been identified in selected patients. 
Cohesin has been implicated in regulation of sister chromatid cohesion, transcription, 
long-range gene interactions and DNA repair(3).  
 
Aberrant CSR patterns have been observed in NIPBL mutated patient’s B-cells(4). 
Here we further investigated whether V(D)J recombination or SHM is affected in 
CdLS patients. In chromosomal-integrated V(D)J reporter assays, a reduced substrate 
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recombination efficiency was observed in NIPBL knockdown human fibroblast- or 
murine pro-B-cells (Fig. E1). We next analyzed the IGH repertoire in five NIPBL and 
three SMC1A mutated CdLS patients (Table E1). The overall diversity of the IGHV 
repertoire, estimated by either the proportion of sequences with a unique CDR3 
divided by the total number of sequences, or by D50, which is a measurement of the 
evenness of the distribution of B cell clones, was significantly lower in the patients 
with NIPBL or SMC1A mutations (Fig. 1a, b). Thus, the CdLS patients had a reduced 
overall diversity of their IGHV regions, with an overrepresentation of large B cell 
clones.  
 
Furthermore, in NIPBL mutated patients with the classical form disease and in 
SMC1A mutated patients, the frequency of IGHV genes located in the most proximal 
one third of the IGH locus (about 250 kb) was increased (Fig. E2a, b, Fig. 1c). The 
observed skewed pattern of VH genes in the patients is likely to be a result of B-cell 
intrinsic changes, as only sequences resulting from unproductive rearrangement 
(successfully rearranged, but out of reading-frame or containing stop codons) were 
included in this analysis and an influence of antigen selection can thus be excluded.  
 
The overall mutation frequency in the unproductive, most commonly mutated IGHV 
genes was also reduced in the CdLS patients, reaching a statistical significance for the 
NIPBL mutated group (Fig. 2a). The proportion of un-mutated sequences was 
increased in the NIPBL mutated patients, especially in those with the classical form of 
disease (Fig. 2a). The pattern of base pair substitution in the V regions was, however, 
largely normal in the patients (Fig. 2b).  
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Our data suggest that the cohesion associated proteins NIPBL and SMC1A are 
involved in the regulation of V(D)J recombination in human B-cells, possibly through 
regulation of locus contraction. Increased usage of proximally located IghV genes has 
previously been observed in mice deficient in factors associated with locus 
contraction, such as Ikaros, Yin Yang 1 and Pax5 and the cohesin interaction partner 
CCCTC binding factor has been suggested to regulate locus contraction and V(D)J 
recombination at the mouse Igh locus(5, 6), (7).   
 
Another possible explanation of how NIPBL/SMC1A could affect V(D)J 
recombination could be a change in regulation of DNA repair. We have previously 
observed a correlation between heterozygous NIPBL loss-of-function mutations and 
increased sensitivity to γ-radiation and a shift towards the use of a microhomology-
based end joining during CSR, suggesting that NIPBL regulates the NHEJ process(4). 
However, the V(D)J coding junctions generated in vivo in CdLS patients showed a 
normal repair pattern (Table E2). Furthermore, the expression of a number of key 
V(D)J recombination factors was largely normal in NIPBL knockdown cells (Fig. 
E3b). Thus, the core NHEJ machinery appears to be retained in CdLS patients.  
 
We also found a reduced frequency of mutations within the IGHV regions in CdLS 
patients. NIPBL and SMC1A could both be involved in the SHM process through 
regulation of transcription or RNA polymerase pausing, which promotes the 
formation of single-stranded DNA and AID targeting. In support of this notion, there 
was a reduced number of mutations observed in the RGYW motifs (containing the 
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AID hotspot in the bottom strand) in NIPBL+/- and SMC1A- cells, suggesting an 
impaired mutagenesis of C residues on the bottom strand (Fig. 2c). We have 
previously observed the opposite pattern in NBS1-deficient cells9. Thus, the targeting 
of AID and/or linked repair seem to be asymmetric during SHM and this can be 
regulated by a number of factors including the cohesin associated factors.  
 
CdLS is not traditionally considered as an immunodeficiency disorder, but these 
patients have an increased prevalence of severe infections10. Immunodeficiency, 
including mild B-cell lymphopenia, reduced switched memory B cells and/ reduced 
serum Ig levels has indeed been observed in previous case reports10 and in our own 
patients (Table E3). Complete knockout of NIPBL is incompatible with survival and 
heterozygous nonsense mutation or frame shift deletions in NIPBL are usually 
associated with a more severe clinical phenotype than those with missense mutations 
and in frame deletions (classical vs. mild form), suggesting a dose dependent role of 
the cohesin associated proteins. The SMC1A mutations are missense or in frame 
deletions and are generally associated with a milder CdLS phenotype. Thus, 
mutations identified in CdLS patients can be considered as hypomorphic and/or result 
in haploinsufficiency, and a more significant alteration in Ig gene diversifications and 
a more severe immunodeficiency would be expected in the event of a complete loss of 
these cohesin associated proteins.  
 
In summary, the less diversified VH genes due a reduced efficiency of V(D)J 
recombination, together with an inefficient CSR efficiency, might contribute to the 
frequent infections in CdLS patients.  
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Figure legends 
 
Fig. 1 Reduced IGH diversities and increased usage of proximal IGHV genes in 
CdLS patients  
a) Diversities (unique/total CDR3s) and b) the proportion of unique B-cell clones that 
account for the cumulative 50 percent of the total CDR3s in the samples, D50, are 
shown. Significant differences compared to controls are indicated by stars, **p<0.01, 
***p<0.001, Student’s t-test. Each dot represents one individual. Black or white 
squares indicate NIPBL mutated patients with the classical or mild form of disease, 
respectively. c) Average frequencies of proximally, middle and distally located V 
genes (in relation to D and J genes) in CdLS patients. Schematic picture (not to scale) 
of the IGH locus on top. Proximal, middle or distal V gene group each encompasses 
approximately 250 kb of the IGHV locus and contains 15, 20 and 19 functional V 
genes respectively. The number of sequences used in the analysis is indicated below 
each group. The proportion of proximal, middle or distal V genes for each individual 
was regarded as one data point, and the patient and control groups were then 
compared by Student t-test. Significant differences compared to controls are indicated 
by arrows. ↑ and ↓, increased or decreased compared to controls, respectively.  
 
Fig. 2 Mutation frequency and substitution pattern in IGHV regions from NIPBL+/- 
and SMC1A- B cells a) Mutation frequencies are shown on the left. Each dot 
represents one individual. Black or white squares indicate NIPBL+/- patients with a 
classical or mild form of disease, respectively. The percentages of sequences with 0, 
1-5, 6-10 or >10 mutations in the IGHV regions from control, NIPBL+/- or SMC1A- 
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cells are depicted in pie charts to the right. IGHV1-18, IGHV1-69, IGHV3-23, 
IGHV3-30, IGHV3-33 and IGHV4-34 sequences were included in the analysis. 
Significant differences as compared to controls are indicated by star(s), *p<0.05; 
Student’s t-test. b) Frequencies of substitutions in the IGHV genes. χ2 test, Bonferroni 
corrected. c) Frequency of mutations within W(A/T)R(G/A)CY(C/T)/RGYW motifs 
in the IGHV genes analyzed in a). Stars indicate significant differences between 
NIPBL+/- (black star), SMC1A- (grey star) compared to control cells, *p<0.05; χ2 test, 
Bonferroni corrected. 
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Supplemental Material and Methods 1 
Patients 2 
Eight CdLS patients were included in the study (Table E1). Five had heterozygous mutations 3 
in the NIPBL gene, of which two (P3, P6) had a more severe, classical form of CdLS, 4 
whereas three (P8, P10, P11) had a milder form of disease. In addition, three male patients 5 
had mutations within the SMC1A gene, located on the X chromosome (SMC1A-1, SMC1A-2 6 
and SMC1A-4). The clinical features of seven of the eight patients have been described 7 
previously1-3. Seven unaffected controls were also included in the study (Table E1). DNA was 8 
isolated from peripheral blood using standard methods. The study was approved by the 9 
institutional review board at the Karolinska Institutet. 10 
 11 
V(D)J recombination substrate assays for assessment of recombination efficiency 12 
A retroviral vector pMX-RSS-GFP/IRES-hCD4 (MX-RSS-INV), which contains an anti-13 
sense-orientated RSS-flanked EGFP reporter and an internal ribosomal entry site (IRES)-14 
linked human CD4 cassette6 was transduced into HEK293FT cells together with three viral 15 
packaging vectors (pGag-Pol, pRev and pVSV-G) by using lipofectamine 2000 (Thermo 16 
Fisher Scientific, Waltham, MA, USA). 48 hours later, the medium containing virus was 17 
collected and used to infect the human fibroblast cell line from an unaffected control. 72 18 
hours later the transduced cells were sorted by flow-cytometry using human CD4 antibody 19 
(Biolegend, San Diego, CA, USA). The CD4+ cells were expanded in the culture for 4 days 20 
and then seeded into 6-well plate (105 cells per well) and treated with either NIPBL or control 21 
siRNA (GE Dharmacon, Lafayete, CO, USA)4 for 48 hours. The cells were subsequently 22 
transfected with 0.9 µg of RAG1 and 0.75 µg RAG2 plasmids using Turbofect (Fermentas, 23 
Waltham, MA, USA). 48 hours after transfection, cells were collected and recombination 24 
activity were assessed as percentages of GFP+ cells by flow-cytometry. This chromosomal 25 
integrated reporter assay allows the assessment of V(D)J recombination and infection 26 
efficiency by measurement of expression of GFP or CD4 respectively. The gene knockdown 27 
efficiency was monitored by real-time PCR (Fig. E1b) as described previously4. 28 
 29 
A murine B-abl pro-B-cell line (with a Bcl2 transgene) carrying the chromosome integrated 30 
MX-RSS-INV substrate was previously described7. The cells were treated with either Nipbl or 31 
control smart pool mouse siRNA (GE Dharmacon, Lafayette, CO, USA) using a nucleofector 32 
kit (Lonza, Basel, Switzerland) for 48 hours and then treated with 0.3 µM abl kinase inhibitor 33 
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(PD-180970, Sigma-Aldrich, St. Louis, MO, USA), which leads to G1 cell cycle arrest and an 34 
induction/stabilization of expression of RAG1/RAG28. Recombination activity were 35 
subsequently assessed as percentages of GFP+ cells by flow-cytometry. The gene knockdown 36 
efficiency was monitored by real-time PCR (Fig. E1c). 37 
 38 
Amplification and high throughput sequencing of IGHV regions from CdLS patients 39 
Ig genes were amplified using a semi-nested PCR as previously described9 with the exception 40 
that 100 ng of genomic DNA and 250 nM of each downstream IGHJ primer were used in the 41 
PCR reaction. Sequencing was performed on the Roche 454 GS FLX Titanium Sequencer 42 
(Agowa GmbH, Germany). V-QUEST10,11, allowing detection of indels, was used to 43 
determine the amino acid sequence of the complementary determining region 3 (CDR3), as 44 
well as the V-, D- and J-genes used. Sequences not spanning the V(D)J-junction were 45 
removed and the remaining sequences were used in subsequent analyses. Any large deletions 46 
that resulted in missing entire CDR3 would therefore not be recorded. The D50-value was 47 
calculated by dividing X with Y and multiplying with 100, where X= number of unique 48 
CDR3s that account for the cumulative 50 percent of the total sequences, Y= number of 49 
unique CDR3s. A sample with an equal distribution of all clones would have a D50 of 50, 50 
whereas a number less than 50 indicates the presence of uneven, larger clones12. Chimeric 51 
sequences, which are artifacts created during the PCR reaction that contains more than one 52 
IGHV region, were detected by visual inspection. If the sequence matched more than one 53 
IGHV gene, at either end, the sequence was omitted from IGHV gene usage analysis. For 54 
SHM analysis, chimeric sequences were also omitted, except if the sequence was chimeric at 55 
the first half of the IGHV region sequence, then the remaining part was still included in the 56 
analysis. Only unique, unproductive sequences (VH and JH genes are not in the same reading 57 
frame or containing premature stop codons) were included for the VH gene usage and SHM 58 
analyses, in order to avoid any antigen selection bias from the expressed repertoire. The error 59 
rate of 454 sequencing was previously determined to be less than 1 error per 1300 bp when 60 
indels were excluded9. 61 
 62 
Real-time PCR 63 
One µg of total RNA was used to synthesize cDNA according to the manufacturer’s protocol 64 
(cDNA synthesis kit, GE Healthcare). Expression of human XRCC6, LIG4, DCLRE1C, 65 
PRKDC or NIPBL in the fibroblast cell line treated with control or NIPBL siRNA was 66 
determined by quantitative real-time PCR assays with a similar setting as described 67 
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previously4. Primer sequences are available upon request. Briefly, the real-time PCR 68 
amplification was performed using the Kapa SYBR Fast qPCR Master Mix kit (Kapa 69 
Biosystems). ACTB was used as housekeeping gene for calculation of relative expression 70 
levels. Expression of Nipbl in the murine B-abl pro-B-cell line treated with control or Nipbl 71 
siRNA was determined by a similar strategy, with mouse Gapdh as housekeeping gene.   72 
 73 
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Table E1: Patients included in study 
Patient Age; Sex Mutation Diagnosis Total seq. 
Productive/ 
Unproductive 
ratioa 
Seq. with unique 
CDR3 Diversity
b
 
Unproductive seq. 
with unique 
CDR3, not 
chimericc 
Reference 
P3 17y; F 
NIPBL+/-,  
c.6250_6255del, 
p.V2084-V2085, deletion 
Classical 
CdLS 806 0.69/0.31 475 0.59 125 
2, 4
 
P6 2y; M 
NIPBL+/-,  
c.4593T>A, p.Y1531X, 
nonsense 
Classical 
CdLS 1874 0.68/0.32 1091 0.58 374 
2, 4
 
P8 4y; F 
NIPBL+/-, 
c.4321G>T, p.V1441L, 
splice sited 
Mild CdLS 11776 0.66/0.34 7070 0.60 1938 1, 4 
P10 10y; M 
NIPBL+/-,  
c.6242G>C, p.G2081A, 
missense 
Mild CdLS 2261 0.66/0.34 1386 0.61 360 1, 4 
P11 14y; M 
NIPBL+/-,  
c.8387A>G, p.Y2796C, 
missense 
Mild CdLS 1191 0.64/0.36 675  0.57 215 This report 
SMC1A-1 2y; M 
SMC1A-,  
c.587G>A, p.R196H, 
missense 
CdLS 2497 0.66/0.34 1489  0.60 405 3, 4 
SMC1A-2 5y; M 
SMC1A-,  
c.3254A>G, p.Y1085C, 
missense 
CdLS 3308 0.68/0.32 2022 0.61 550 3, 4 
SMC1A-4 9y; M 
SMC1A-,  
c.3568A>G, p.K1190E, 
missense 
CdLS 2163 0.66/0.34 1390  0.64 402 4 
C19 19y; M - Unaffected 276 0.62/0.38 210  0.76 41 This report 
C31 19y; ? - Unaffected 316 0.62/0.38 257  0.81 71 This report 
C34 13y; ? - Unaffected 660 0.65/0.35 506  0.77 113 This report 
C54 13y; ?  - Unaffected 1840 0.63/0.37 1272  0.69 321 This report 
gConte 2y, 5y, 7y; ? - Unaffected 3482 0.53/0.47 2845 0.82 1033 This report 
          
a. Productive: as a result of V(D)J recombination, the VH, DH and JH genes are in the correct translational reading-frame.  
b. Diversity was calculated by dividing sequences with unique CDR3s with the total sequences. Sequences not spanning the CDR3 region were omitted from calculation. 
c. Only unproductive rearrangement (out of reading-frame or contain a stop codon), unique sequences, not chimeric at both ends, were included in V gene analysis. 
d. This mutation has been shown to yield two transcripts, of which one bears an exon 20 deletion and the other is of ordinary size but with a V1441L change1. 
e. gCont contained a pool of DNA from 3 individuals. y: years; F: female; M: male; seq.: sequence. 
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Table E2: Characterizationa of in vivo generated V(D)J coding junctionsb 
Study groups Average CDR3 lengths (bp) 
Average no. of P 
nts (bp) 
Average no. of 
N nts (bp) 
NIPBL+/- 53.1 0.46 13.5 
    
SMC1A- 53.5 0.50 14.5 
    
Controls 53.1 0.48 14.2 
a. Statistical calculations were performed by Student’s t-test. No significant differences were found. 
b. The calculations were based on unique sequences. 
CDR3: complementary determining region 3; no.: number; bp: base pair; P nts: Palindromic 
nucleotides; N nts: non-template nucleotides 
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Table E3: Immunological data of CdLS patients P6, P8, P10, P11, SMC1A-1 and SMC1A-2 
a. Normal range, from immunological center where measurement was taken, is indicated in parenthesis. Values below the normal range are indicated in bold.  
b. Measured after stimulation with IL4, CD40L, CD40L+IL4, NS-BAFF_TH3, BAFF_TH3, BAFF+µ_TH3 or CpG+µ_TH3, NS, non-stimulated; TH3, thymidine incorporation 
c. Measured after stimulation with CD40L+IL4 for switching to IgE. NA, not analysed
 
P6 (classical CdLS) P8 (mild CdLS) P10 (mild CdLS) P11 (mild CdLS) SMC1A-1 SMC1A-2 
Age at sampling 14Y 4Y 10Y 14Y 8Y 11Y 
Lymphocytesa       
Proportion of lymphocytes  31% (22-50) NA 35.5% (20-45) 33.4% (20-45) NA NA 
Total lymphocytes  2100 mm3 (1000-5500) NA 1700 mm3 (1500-4500) 1700 mm3 (1500-4500) 3400 mm3 3300 mm3 
       
T lymphocytesa       
T lymphocytes, CD3+ 84% (52-78) NA 66% (63-84) 70% (65-80) NA NA 
T lymphocytes, CD4+  51% (25-48) NA 42% (33-57) 33%↓ (40-50) NA NA 
T lymphocytes, CD8+  26% (9-35) NA 20% (14-39) 32% (26-30) NA NA 
CD4/CD8 ratio  1.96 (0.9-3.4) NA 2.1 (1.5-2) 1.03↓ (1.5-2) NA NA 
T lymphocytes, CD4+ 1110 mm3 (400-2100) NA 715.68 mm3 (400-1535) 551.1 mm3 (500-800) NA NA 
T lymphocytes, CD8+ 570 mm3 (200-1200) NA 340.8 mm3 (139-1015) 534.4 mm3 (250-800) NA NA 
NK cells, CD56+ 5%↓ (6-27) NA 8% (7-21) 5% (5-10) NA NA 
       
B lymphocytesa       
Proportion B lymphocytes, CD19+ 8% (8-24) NA 19% (7-22) 19% (10-15) 12%↓ (13-27) 5%↓ (13-27) 
Total B lymphocytes, CD19+ 160 mm3↓ (200-600) NA NA NA 408 mm3 (270-860) 165 mm3↓ (270-860) 
CD21++CD24+/CD19+ NA NA NA NA 84% 84% 
CD21+CD24++/CD19+ NA NA NA NA 1.7% 1.2% 
CD21-CD24-/CD19+ NA NA NA NA 5% 5% 
CD27+/CD19+ NA NA NA NA 31% (>10) 16% (>10) 
CD27+IgD+/CD19+ (Marginal zone) 15% (6-29) NA NA NA 21% 8% 
IgM+IgD+/CD19+ NA NA NA NA 78% 63% 
IgM+IgD+/CD27+CD19+ NA NA NA NA 63% 37% 
IgM+IgD-/CD27+CD19+ NA NA NA NA 16% 8% 
IgM-IgD-/CD27+CD19+ NA NA NA NA 17% (>10) 46% (>10) 
CD21-CD38-/CD19+ NA NA NA NA 5% 3.7% 
IgD+CD27- (Naive) 78% (47-84) NA NA NA NA NA 
IgD-CD27+ (Switched memory) 4%↓ (8-29) NA NA NA NA NA 
IgM-CD38+ (Plasma blasts) 1% (0-3.2) NA NA NA NA NA 
IgM++CD38++ (Transitional) <0.5% (<1) NA NA NA NA NA 
B-CD21-CD38- (CD21 low) 1% (<4) NA NA NA NA NA 
       
B cell proliferationb NA NA NA NA NA Normal 
      
 
Immunoglobulinsa       
IgM 1.71 g/L (0.27-2.1) 0.59 g/L (0.27-2.1) 56.2 mg/dL↓ (60-263) 65.4 mg/dL (50-268) NA 1.47 g/L (0.53-1.62) 
IgG 14.5 g/L (6.1-14.5) 9.65 g/L (6.1-14.5) 754 mg/dL↓ (768-1632) 825 mg/dL (768-1632) NA 14.97 g/L (6.55-12) 
IgA 2.82 g/L (0.7-3.65) 0.98 g/L (0.5-2.3) 63.5 mg/dL↓ (68-378) 180 mg/dL (68-378) NA 1.89 g/L (0.5-2.03) 
Ig switchingc NA NA NA NA NA Positive, but weak 
       
Specific immunoglobulins       
S-Difteri-ak (IgG) NA 0.2 IE/mL (0.01-3.0) NA NA NA NA 
S-Tetanus-ak (IgG)  NA 0.25 IE/mL (0.09-12.87) NA NA NA NA 
S-Tetanus-ak (IgG1)  0.75 mg/L↓ (4.9-180) 2.9 mg/L (0.9-228.5) NA NA NA NA 
S-Haemophilus-ak (IgG)  NA 0.14 mg/L↓ (0.15-29.5) NA NA NA NA 
S-Pneumokock-ak (IgG2)  NA 11 mg/L (0.8-122.4) NA NA NA NA 
S-Pneumokock-ak (IgG)  NA 25 mg/L (9.2-225.9) NA NA NA NA 
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Figure E1: V(D)J recombination substrate assays in a human fibroblast cell line and 
a murine pro-B-cell line.  
a) Schematic picture of the pMX-RSS-GFP/IRES-hCD4 (MX-RSS-INV) construct.  
b) Expression of NIPBL in a human fibroblast line stably transfected with the MX-RSS-
INV) construct and c) expression of Nipbl in a mouse pro-B cell line stably transfected 
with the same construct were measured by real-time PCR. The expression of NIPBL or 
Nipbl was reduced by 19% or 36% with the scrambled control siRNAs and by 80% or 
74% after specific NIPBL or Nipbl siRNA treatment. 
d) Chromosomal-integrated V(D)J reporter assay in human fibroblast cells. The V(D)J 
reporter MX-RSS-INV was retrovirally transduced into a human fibroblast cell line from 
an unaffected control. CD4 positive cells were FACS sorted and expanded and tested (see 
supplemental M&M). GFP positive cells are indicative of successful recombination. 
Statistical calculation was performed with Student’s t-test. The results represent two 
independent experiments. 
e) V(D)J reporter assay in a murine B-Abl pro-B-cell line carrying the chromosome 
integrated MX-RSS-INV substrate. GFP positive cells are indicative of successful 
recombination. Statistical calculation was performed with Student’s t-test. The results 
represent two independent experiments.  
 
Fig. E2. Frequencies of individual IGHV genes in unproductive sequences in a) classical 
NIPBL and b) SMC1A mutated B-cells from CdLS patients are shown. Statistical calculations 
were performed by Student’s t-test, and significant differences compared to controls are 
indicated by arrows. ↑ and ↓, increased or decreased compared to controls, respectively. 
 
    
Fig. E3. Expression of genes analysis in NIPBL knockdown cells. Expression of NIPBL in 
a human fibroblast line (a) was measured by real-time PCR. The expression of NIPBL was 
reduced by 21% with the scrambled control siRNAs and by 77% after specific NIPBL siRNA 
treatment. b) Expression of genes involved in V(D)J recombination in a human fibroblast cell 
line. The results represent an average of two independent experiments. RQ: relative 
quantification; Ctrl: control; (-): untreated 
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